Signifier Medical Technologies

Improving the quality of life, sleep and relationships by tackling a root cause of snoring: eXciteOSA.

sleep apnea

Driving Innovation in the Sleep Market

Signifier Medical Technologies (SMT), previously known as eXciteOSA® , is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.

Pioneers in challenging the wisdom of conventional snoring and sleep apnea treatments, we’ve created the first daytime therapy that tackles the root cause of sleep disordered breathing by physiologically retraining the airway against collapse.

The Vision of Signifier Medical Technologies: eXciteOSA

We aspire to revolutionize sleep apnea therapy with the novel and ground-breaking eXciteOSA sleep apnea device that will help solve the conditions of snoring and mild sleep apnea, making a real impact on the lives of millions of people globally, in an area with significant unmet medical needs.

Working with a multidisciplinary team, eXciteOSA® co-founder Professor Akhil Tripathi, was deeply empathetic with many patients who struggle with conventional treatment options for Sleep Disordered Breathing which have failed to change in the last two decades.

Professor Tripathi is a serial medical device entrepreneur with experience bringing innovative products to medical practice improving patients’ lives.

As an innovator, Professor Tripathi is committed to revolutionizing healthcare with truly creative approaches and not merely optimizing existing approaches to their next evolution.

There are many devices for Sleep Disordered Breathing. All of which have problems:

  • They had to be worn during sleep
  • Many were invariably uncomfortable
  • Only treated the symptom, not the cause
  • Only effective when in use
  • Further disrupted the already poor sleep quality
  • Only temporarily alleviated the problem

Wanting to disrupt this dependence on products that have to be worn during sleep, Professor Tripathi developed the world’s first, unique daytime treatment for sleep disordered breathing – eXciteOSA® .

Three years of devoted effort by many highly skilled professionals from sleep medicine, maxilofacial surgery, product development, medical engineering, software engineers and regulatory experts, has led to a simple, intuitive, non-intrusive and safe product that is clinically proven to treat the root cause of sleep disordered breathing.

of bed partners reported reduction of their partners snoring1
of patients reported reduction in snoring time1

Akhil Tripathi

Board Member & Co-Founder

Shahzada Ahmed

Board Member

John Bentley

Board Member

Mujtaba Chohan

Board Member

Rupert Connell

Board Member

Rupert Reid

Board Member

Andrew Schumer

Board Member

Chris Tuohy

Board Member

Yasser Zayni

Board Member

Peter Cistulli

Peter Cistulli holds the ResMed Chair in Sleep Medicine at the University of Sydney, where he leads the Sleep Research Theme within the multidisciplinary Charles Perkins Centre. Prof Cistulli is also a former President of the Australasian Sleep Association and a former board member of the Sleep Health Foundation.

Aditi Desai

Dr Aditi Desai is the President of the British Society of Dental Sleep Medicine (BSDSM) and an expert dental surgeon with a special interest in sleep medicine. She has served on the Odontological Council and Sleep Medicine Council of the Royal Society of Medicine (RSM) and is on the Board for the Association for Respiratory Technology and Physiology, UK (ARTP).

Richard Schwab

Dr Richard Schwab is a professor of medicine at the Hospital of the University of Pennsylvania and is affiliated with Hospitals of the University of Pennsylvania-Penn Presbyterian. Dr Schwab’s groundbreaking research has focused on the pathogenesis of obstructive sleep apnea utilising novel upper airway imaging techniques.


  1. Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period